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Abstract
Background: Pre- analytical factors, like freeze- thaw cycles (FTC), can potentially affect 
results and clinical interpretation. According to the SSC- ISTH recommendations for 
 antiphospholipid antibodies (aPL) testing, additional FTC should be avoided to maintain 
the best performance. Patient samples are often analyzed in batch and having one frozen 
sample aliquot for all aPL tests, that may hamper daily routine work- out. To use them for 
study or method validation purpose, sample storage in bio banks is often done in one 
 aliquot also triggering the need for several FTC to be able to use them in different scien-
tific projects. Taking into account the limited scientific literature, the strict guidelines and 
the potential benefits of repeated FTC we evaluated this pre- analytical factor.
Objectives: Evaluating the effect of repeated FTC on anticardiolipin (aCL) IgM/IgG 
and anti- beta- 2 glycoprotein 1 (aβ2GPI) IgM/IgG antibody titer.
Patient/Methods: 42 patient plasmas that were not thawed before, were retrieved 
from the routine archive (−80°C). All aliquots were analyzed on five consecutive days 
with an additional, standardized FTC every day. Mann- Withney tests for statistical 
differences and a concordance correlation coefficient (CCC) were calculated between 
the first and following FTC.
Results and Conclusion: For all four aPL no statistical difference or degradation from 
positive to negative was seen, even after five FTC. The CCC between the first and fifth 
FTC were between 0.98 and 1 for all four aPL. aCL IgM/IgG and aβ2GPI IgM/IgG 
 antibody titer, over a broad titer range, are stable over time and after repeated FTC.
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Essentials
• Limited data are available of freeze-thaw effect on anticardiolipin and anti-beta2-glycoprotein I antibodies.
• Patient samples with antibody titer over a broad range were analyzed in a standardized freezing-thawing scheme.
• aCL and aβ2GPI IgG and IgM titers are stable over time and after repeated freeze-thawing.
• Repeated use of samples facilitates routine work-out and use of samples for scientific purposes.
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1  | INTRODUCTION
Beside clinical symptoms, the diagnosis of antiphospholipid syndrome 
(APS) is based on the presence of persistent antiphospholipid anti-
bodies (aPL). The three main cornerstone antibodies are anticardio-
lipin (aCL) IgM/IgG, anti- beta- 2 glycoprotein 1 antibodies (aβ2GPI) 
IgM/IgG, and lupus anticoagulant (LAC). Among many challenges in 
aPL measurement, the pre- analytical conditions may influence test 
results.1,2 Following the Standardization subcommittee (SSC) of the 
international society of thrombosis and haemostasis (ISTH) recom-
mendations, FTC should be avoided for all aPL.3,4 In contrast to the 
effect of freeze- thawing in phospholipid- dependent clotting assays 
used for LAC, there is little scientific literature for solid phase assays 
(SPA).5 However, APL testing is mainly performed in batch due to 
the potential negative influence of pre- analytical variables, such as 
repeated FTC, on test results.
Evaluating the effect of repeated FTC on aCL IgM/IgG and aβ2GPI 
IgM/IgG could generate practical benefits for routine testing. Another 
useful application could be the use of stored samples for research and 
method evaluations.
2  | METHODS
Patient plasmas (n = 42) were selected based on routine results to 
cover a wide titer range for all four APL, and on availability of an 
unthawed aliquot (Table 1).
Citrated plasma was frozen after double centrifugation.3 Samples 
were collected between 2012 and 2017. First analysis of each included 
sample was performed on aliquot not thawed before. Further, samples 
were analyzed on five consecutive days with an additional, standard-
ized FTC every day (Figure 1). All analysis were performed by an auto-
mated chemiluminescent assay (HemosIL AcuStar, Instrumentation 
Laboratory- Werfen, Bedford, MA, USA) using the same reagent lot for 
each parameter during the study.
Statistical analysis was done in Medcalc (MedCalc Statistical 
Software version 16.4.3 (MedCalc Software bvba, Ostend, Belgium). 
A Mann- Withney test for statistical differences (P < .05) between the 
first and following FTC was performed. If no statistical difference was 
obtained after five FTCs, a concordance correlation coefficient (CCC) 
was calculated.
TABLE  1 Routine results for all selected patient samples (n = 42) stored in the routine archive
Negative Around Cut off Positive Strong positive
Range (U/ml) # samples Range (U/mL) # samples Range (U/ml) # samples Range (U/mL) # samples
aCL IgG 3- 12 8 21- 34 6 53- 54 3 103- 480 10
aCL IgM 2- 18 7 22- 27 4 52- 70 7 104- 2330 6
aβ2GPI IgM 3- 9 7 21- 48 8 54- 88 3 107- 2705 6
aβ2GPI IgG 11- 18 9 23- 97 12 119- 186 4 213- 3153 12
aCL, anticardiolipin; aβ2GPI, anti-beta 2 glycoprotein I.
F IGURE  1 Timelaps studydesign 
*Thawing (37°C water bath 5 minutes); 
**Start analysis (every day in same order); 
***Freezing of all samples at −20°C
Day 1
10 AM
10:30 AM
4 PM Freeze*** Freeze*** Freeze*** Freeze*** Freeze***
Analyse** Analyse** Analyse** Analyse** Analyse**
Thaw* Thaw* Thaw* Thaw* Thaw*
Day 2 Day 3 Day 4 Day 5
TABLE  2 Overview of Mann- Withney test results between the first and following freeze thaw cycle
Samples
FTC1 
med(IQR)
FTC2 med 
(IQR)
P- value 
(FTC1- 2)
FTC3 med 
(IQR)
P- value 
(FTC1- 3)
FTC4 med 
(IQR)
P- value 
(FTC1- 4)
FTC5 med 
(IQR)
P- value 
(FTC1- 5)
aCL IgG 26 30(8- 93) 32 
(13- 263)
.8692 33(13- 274) .7418 35(147- 237) .7349 34(13- 276) .7143
aCL IgM 24 55(13- 87) 57(11- 88) .8528 58(11- 90) .765 59(11- 86) .7259 57(8- 76) .8481
aβ2GPI 
IgM
25 31(8- 93) 28(9- 98) .8234 31(8- 99) .6908 29(9- 102) .7784 31(8- 81) .7949
aβ2GPI 
IgG
37 74(22- 676) 73(18- 724) .9354 79(15- 694) .8642 74(11- 748) .9058 74(13- 723) .9551
aCL, anticardiolipin; aβ2GPI, anti-beta 2 glycoprotein I.
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3  | RESULTS AND DISCUSSION
To exclude long term storage as a potential source of degradation, all 
aPL titers after one FTC were compared with the original results (ini-
tially also obtained after one FTC). No significant differences between 
these results were observed. An interesting feature of these results, 
knowing that some of these samples were already stored for 5 years, 
is the stability over time. Having a closer look at samples stored frozen 
for more than 2 years, no significant difference was seen between the 
initial results and the results after one FTC in the current study. The sam-
ple results, 8 for aCL IgG, aCL IgM aβ2GPI IgM, and 13 for aβ2GPI IgG, 
showed an excellent correlation coefficient (0.94- 0.99) between the ini-
tial results and the result after one FTC obtained in this study. Due to the 
limited number of samples stored more than three years, no useful sta-
tistical analysis could be performed to confirm an even longer stability.
After five FTC, none of the samples degraded from positive to 
negative and no false positive results were seen. Also, no significant 
titer changes (defined as > 10%) were seen after five FTC. Between 
the first and following repeated FTCs a Mann- Withney test was per-
formed for all aPL to look for statistical significant differences in titer 
(Table 2). Even after five FTC none of the aPL tested gave a significant 
difference in results. A correlation between the titers was calculated 
and illustrated in Figure 2, showing graphically and mathematical, the 
good correlation for all four aPL with a CCC between 0.98 and 1.
Considering the high CCC, we could exclude a significant inter- 
run variability as potential influencing factor on variability of titers. 
For each sample, a coefficient of variation (CV) was calculated using 
the test result after each FTC. Comparing the median CV value (for 
each aPL divided in four categories as described in Table 1) with results 
obtained from quality control (QC) material no significant difference 
was found. All median sample CV values varied between 4 and 15.6% 
comparing to the QC CV values of these runs, between 2.3- 13.9%. 
These results confirm the stable character of the antibodies and the 
limited effect of FTC.
Furthermore, 4 months later, a selection of these samples with suf-
ficient sample volume, were additionally thawed and analyzed using 
another batch of reagent. No significant differences were observed 
between first FTC and these results. As a final test, these samples 
were also analyzed on a second analyzer of the same type, also result-
ing in non- significant differences. Correlating results after the first 
FTC on analyzer 1 and results after the sixth FTC on a second ana-
lyzer a concordance correlation coefficient was found, depending on 
the antibody, between 0.91- 0.98. Comparing both analyzers, with a 
sample size varying between 13 and 23 samples, an excellent correla-
tion coefficient of 0.99 for each antibody was found, confirming the 
robustness of this automated systems.6
aPL are very heterogeneous group of antibodies. The small sample 
size, although covering a broad titer range, may be seen as a limitation 
of this study. Also, all tests were performed using one and the same 
analytical platform. Other test systems are known to be less robust 
suffering from lab to lab variation or high between- run variation.6,7 
Using this automated system excludes these variables, making it pos-
sible to exclusively evaluate the effect of freeze- thaw cycles.
4  | CONCLUSION
We evaluated the stability of aPL titers after several FTC. aCL and 
aβ2GPI IgG and IgM, over a broad titer range including samples 
around the cut- off value, are stable over time and after repeated FTC. 
With this study, we excluded this pre- analytical factor as source for 
variability in aPL titer measured by chemiluminescent assays.
F IGURE  2 The CCC calculated between 
first and fifth FTC are graphically shown. 
Values above 200 U/mL are disregarded in 
the graph (for visual purposes), but were 
included in the concordance correlation 
coefficient calculation and showed 
no significant difference with values 
below 200 IU/ml aCL, anticardiolipin; 
aβ2GPI, anti- beta- 2 glycoprotein 1; CCC, 
concordance correlation coefficient; FTC, 
freeze- thaw cycle
160 Concordance correlation coefficient for all four aPL.
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